ExpreS2ion to present in Redeye Fight Cancer event and the Bio Innovation Leaders Summit
Hørsholm, Denmark, 22 January 2024 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") will participate in investor and R&D events in the coming weeks. This Wednesday, January 24th, CEO Bent Frandsen will present at the Redeye thematic event, Fight Cancer. Furthermore, Senior VP of R&D and Technology Dr. Max Søgaard will present at the Bio Innovation Leaders Summit taking place on February 7th and 8th.
By attending relevant industry and investor events, the company aims to increase the awareness of its technology platform and its exciting development pipeline. More information on each event and how to register is found below and on the Company’s website.
24 January 2024 | Redeye thematic event: Fight Cancer
12:45 CET | Stockholm, Sweden
Join us at Redeye's thematic event, Fight Cancer, in Stockholm, on January 24th at 12:45 CET. CEO Bent Frandsen will present ExpreS2ion's therapeutic breast cancer vaccine program ES2B-C001 (HER2-cVLP). Learn more and register as a Redeye member to attend via Redeye's website.
7-8 February 2024 | Bio Innovation Leaders Summit
Barcelona, Spain
ExpreS2ion Senior Vice President of R&D and Technology Dr. Max Søgaard is invited to present at the 16th Annual Bio Innovation Leaders Summit, to be held at the Hyatt Regency Barcelona Tower in Barcelona, Spain from 7 to 8 February 2024. For more information and to attend the event, please visit the Bio Innovation Leaders Summit website. To set up a meeting with Dr. Søgaard, please send a meeting request to info@expres2ionbio.com.
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
For further information about ExpreS2ion Biotech Holding AB, please contact:
Bent U. Frandsen, CEO
Keith Alexander, CFO
E-mail: investor@expres2ionbio.com
About ExpreS2ion
ExpreS2ion is a biotechnology company that develops innovative vaccines for a healthier world. We want to transform healthcare by developing novel vaccines, that are life-saving and improving quality of life across the world. ExpreS2ion has developed the unique human clinical Phase III-validated technology platform, ExpreS2™, for fast and efficient development and production of the active material in vaccines. The platform, under the brand GlycoX-S2™, includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, ExpreS2ion has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with leading research institutions and companies. ExpreS2ion develops novel VLP based vaccines in association with AdaptVac ApS, of which ExpreS2ion owns 34%. For additional information, please visit www.expres2ionbio.com.